Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

PLEIADES: Daratumumab combinations for multiple myeloma

Dr Ajai Chari - Mount Sinai, New York City, USA
PLEIADES: Daratumumab combinations for multiple myeloma ( Dr Ajai Chari - Mount Sinai, New York City, USA )
25 Sep 2019

Treatment options for high risk relapsed/refractory multiple myeloma

Dr James Berenson - Oncotherapeutics, West Hollywood, USA
Treatment options for high risk relapsed/refractory multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )
25 Sep 2019

Ruxolitinib, lenalidomide and methylprednisolone for relapsed/refractory multiple myeloma

Dr James Berenson - Oncotherapeutics, West Hollywood, USA
Ruxolitinib, lenalidomide and methylprednisolone for relapsed/refractory multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )
25 Sep 2019

ICARIA: Isatuximab, pomalidomide and dexamethasone in relapsed/refractory multiple myeloma

Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia
ICARIA: Isatuximab, pomalidomide and dexamethasone in relapsed/refractory multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )
25 Sep 2019

BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed/refractory multiple myeloma

Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia
BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed/refractory multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )
25 Sep 2019

Successful implementation of biosimilars through effective communication

Dr Pauline Leonard - The Whittington Hospital, London, UK
Successful implementation of biosimilars through effective communication ( Dr Pauline Leonard - The Whittington Hospital, London, UK )
25 Sep 2019

Continuous treatment versus fixed duration therapy: Using real-world evidence to guide treatment paradigms for multiple myeloma

Prof Evangelos Terpos, Prof Andrew Spencer and Dr Robert Rifkin
Continuous treatment versus fixed duration therapy: Using real-world evidence to guide treatment paradigms for multiple myeloma ( Prof Evangelos Terpos, Prof Andrew Spencer and Dr Robert Rifkin )
23 Sep 2019

Appraising an NTRK testing algorithm: When, what, how

Professor Jean-Yves Blay and Professor Frédérique Penault-Llorca
Appraising an NTRK testing algorithm: When, what, how ( Professor Jean-Yves Blay and Professor Frédérique Penault-Llorca )
16 Sep 2019

Optimising regorafenib dosing in mCRC

Dr Axel Grothey and Dr Tanios Bekaii-Saab
Optimising regorafenib dosing in mCRC ( Dr Axel Grothey and Dr Tanios Bekaii-Saab )
2 Aug 2019

Evaluating treatment options for acute myeloid leukaemia

Dr Amanda Brahim - Memorial Healthcare System, Hollywood, FL, USA
Evaluating treatment options for acute myeloid leukaemia ( Dr Amanda Brahim - Memorial Healthcare System, Hollywood, FL, USA )
26 Jul 2019

Cancer control in Africa - Special Issue

Prof Twalib Ngoma - Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
Cancer control in Africa - Special Issue ( Prof Twalib Ngoma - Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania )
25 Jul 2019

Radiotherapy for liver cancer, and neoadjuvant therapy for rectal cancer

Dr Parag Parikh - Mayo Clinic, Rochester, USA
Radiotherapy for liver cancer, and neoadjuvant therapy for rectal cancer ( Dr Parag Parikh - Mayo Clinic, Rochester, USA )
17 Jul 2019